This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Walker-Daniels, J. Articles by Kinch, M. S. Search for Related Content PubMed PubMed Citation Articles by Walker-Daniels, J. Articles by Kinch, M. S.

---

Signaling and Regulation

c-Cbl-Dependent EphA2 Protein Degradation Is Induced by Ligand Binding¹

Departments of ¹ Basic Medical Sciences and ² Medicinal Chemistry and Molecular Pharmacology, Purdue University Cancer Center, West Lafayette, IN; and
³ MedImmune, Inc., Gaithersburg, MD

Requests for reprints: Michael S. Kinch, MedImmune, Inc., 35 West Watkins Mill Road, Gaithersburg, MD 20878. Phone: (240) 632-4639; Fax: (301) 527-4200. E-mail: kinchm{at}medimmune.com

The EphA2 receptor protein tyrosine kinase is overexpressed and functionally altered in a large number of human carcinomas. Despite its elevated levels in cancer, the EphA2 on the surface of malignant cells demonstrates lower levels of ligand binding and tyrosine phosphorylation than the EphA2 on non-transformed epithelial cells. In our present study, we demonstrate that ligand-mediated stimulation causes EphA2 to be internalized and degraded. The mechanism of this response involves ligand-mediated autophosphorylation of EphA2, which promotes an association between EphA2 and the c-Cbl adaptor protein. We also show that c-Cbl promotes stimulation-dependent EphA2 degradation. These findings are important for understanding the causes of EphA2 overexpression in malignant cells and provide a foundation for investigating EphA2 as a potential target for therapeutic intervention.

This article has been cited by other articles:

				R. Noberini, M. Koolpe, S. Peddibhotla, R. Dahl, Y. Su, N. D. P. Cosford, G. P. Roth, and E. B. Pasquale Small Molecules Can Selectively Inhibit Ephrin Binding to the EphA4 and EphA2 Receptors J. Biol. Chem., October 24, 2008; 283(43): 29461 - 29472. [Abstract] [Full Text] [PDF]

				W. B. Fang, D. M. Brantley-Sieders, Y. Hwang, A.-J. L. Ham, and J. Chen Identification and Functional Analysis of Phosphorylated Tyrosine Residues within EphA2 Receptor Tyrosine Kinase J. Biol. Chem., June 6, 2008; 283(23): 16017 - 16026. [Abstract] [Full Text] [PDF]

				J. Wykosky, D. M. Gibo, and W. Debinski A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells Mol. Cancer Ther., December 1, 2007; 6(12): 3208 - 3218. [Abstract] [Full Text] [PDF]

				R Holm, S Knopp, Z Suo, C Trope, and J M Nesland Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis J. Clin. Pathol., October 1, 2007; 60(10): 1086 - 1091. [Abstract] [Full Text] [PDF]

				A. B. Larsen, M. W. Pedersen, M.-T. Stockhausen, M. V. Grandal, B. v. Deurs, and H. S. Poulsen Activation of the EGFR Gene Target EphA2 Inhibits Epidermal Growth Factor-Induced Cancer Cell Motility Mol. Cancer Res., March 1, 2007; 5(3): 283 - 293. [Abstract] [Full Text] [PDF]

				G. Zhuang, S. Hunter, Y. Hwang, and J. Chen Regulation of EphA2 Receptor Endocytosis by SHIP2 Lipid Phosphatase via Phosphatidylinositol 3-Kinase-dependent Rac1 Activation J. Biol. Chem., January 26, 2007; 282(4): 2683 - 2694. [Abstract] [Full Text] [PDF]

				D. Pfaff, U. Fiedler, and H. G. Augustin Emerging roles of the Angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking J. Leukoc. Biol., October 1, 2006; 80(4): 719 - 726. [Abstract] [Full Text] [PDF]

				S. Abraham, D. W. Knapp, L. Cheng, P. W. Snyder, S. K. Mittal, D. S. Bangari, M. Kinch, L. Wu, J. Dhariwal, and S. I. Mohammed Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder Clin. Cancer Res., January 15, 2006; 12(2): 353 - 360. [Abstract] [Full Text] [PDF]

				M. Parri, F. Buricchi, M. L. Taddei, E. Giannoni, G. Raugei, G. Ramponi, and P. Chiarugi EphrinA1 Repulsive Response Is Regulated by an EphA2 Tyrosine Phosphatase J. Biol. Chem., October 7, 2005; 280(40): 34008 - 34018. [Abstract] [Full Text] [PDF]

				J. Wykosky, D. M. Gibo, C. Stanton, and W. Debinski EphA2 as a Novel Molecular Marker and Target in Glioblastoma Multiforme Mol. Cancer Res., October 1, 2005; 3(10): 541 - 551. [Abstract] [Full Text] [PDF]

				M. Hu, K. L. Carles-Kinch, D. P. Zelinski, and M. S. Kinch EphA2 Induction of Fibronectin Creates a Permissive Microenvironment for Malignant Cells Mol. Cancer Res., October 1, 2004; 2(10): 533 - 540. [Abstract] [Full Text] [PDF]

				P. H. Thaker, M. Deavers, J. Celestino, A. Thornton, M. S. Fletcher, C. N. Landen, M. S. Kinch, P. A. Kiener, and A. K. Sood EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma Clin. Cancer Res., August 1, 2004; 10(15): 5145 - 5150. [Abstract] [Full Text] [PDF]

				R. L. Pratt and M. S. Kinch Ligand Binding Up-Regulates EphA2 Messenger RNA Through the Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Pathway Mol. Cancer Res., December 1, 2003; 1(14): 1070 - 1076. [Abstract] [Full Text] [PDF]

				K. T. Coffman, M. Hu, K. Carles-Kinch, D. Tice, N. Donacki, K. Munyon, G. Kifle, R. Woods, S. Langermann, P. A. Kiener, et al. Differential EphA2 Epitope Display on Normal versus Malignant Cells Cancer Res., November 15, 2003; 63(22): 7907 - 7912. [Abstract] [Full Text] [PDF]

				K. K. Murai and E. B. Pasquale `Eph'ective signaling: forward, reverse and crosstalk J. Cell Sci., July 15, 2003; 116(14): 2823 - 2832. [Abstract] [Full Text] [PDF]

				J. Walker-Daniels, A. R. Hess, M. J.C. Hendrix, and M. S. Kinch Differential Regulation of EphA2 in Normal and Malignant Cells Am. J. Pathol., April 1, 2003; 162(4): 1037 - 1042. [Full Text] [PDF]